Binimetinib

Mektovi®

Inhibition of MEK kinases 1 and 2. The MEK kinases are phosphorylated and activated by the mutated V600-BRAF kinases (MAP kinase signaling pathway).

12/2019

In combination with encorafenib: unresectable or metastatic melanoma with a BRAF V600 mutation.

Off-label in cases of NRAS mutation as monotherapy, in uveal melanomas, or in melanomas arising from congenital nevi with NRAS mutation mosaicism.

Differential blood count, blood chemistry panel, glucose, high-sensitivity troponin T, troponin I, NT-proBNP, S-100, blood pressure, ECG (QT interval < 500 ms), echocardiography (LVEF > 50%).

Dermatological examination.

Ophthalmological examination (if ophthalmological symptoms are present).

Once a month: Differential blood count, blood chemistry panel, glucose, S-100, blood pressure.

Once a month through month 3, then once a quarter: ECG (QT interval).

Dermatological examination: once per quarter.

After 4 weeks, then once per quarter: echocardiography, high-sensitivity troponin T, troponin I, NT-proBNP.

Ophthalmological examination in case of changes in visual acuity.

Treatment should be continued until the patient no longer derives benefit from it or unacceptable toxicity occurs.

45 mg twice daily orally, in combination with encorafenib.

Use caution when taking this medication concurrently with strong CYP2C8 and CYP3A4 inhibitors (e.g., grapefruit, itraconazole) or inducers (e.g., St. John's wort, rifampicin, phenytoin, carbamazepine).

See medical literature, guidelines, and study results.